Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.

Gynecologic oncology - 1 Dec 2024

Kilowski Karolina A, Dietrich Martin F, Xiu Joanne, Baca Yasmine, Hinton Andrew, Ahmad Sarfraz, Herzog Thomas J, Thaker Premal, Holloway Robert W

Abstract excerpt

BACKGROUND/OBJECTIVES: Patients with recurrent or metastatic endometrial cancer (EC) have poor prognoses with limited therapeutic options following immunotherapy or immunochemotherapy treatments. Inhibitors of KRAS mutations (KRAS-mut) have shown efficacy in early solid tumor studies, but data in EC are lacking. This study describes the frequency of KRAS-mut relative to other oncogenic alterations in EC to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Endometrial Neoplasms

Share to Immunotherapy

Share to Microsatellite Instability

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 39500247
DOI: 10.1016/j.ygyno.2024.10.026

Genes

KRAS
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.PMID 39500247Read ↗

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers.Semantic proximity Read ↗

Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.Semantic proximity Read ↗

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.Semantic proximity Read ↗

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently MutatedSemantic proximity Read ↗

Clinical relevance of oncogenic driver mutations identified in endometrial carcinomaSemantic proximity Read ↗

Clinical Relevance of Oncogenic Driver Mutations Identified in Endometrial CarcinomaSemantic proximity Read ↗

Met Mutation is a Potential Therapeutic Target for Advanced Endometrial Cancer Semantic proximity Read ↗

KRAS Mutations in Mucinous Lesions of the Uterus.Semantic proximity Read ↗

The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.Semantic proximity Read ↗

Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer.Semantic proximity Read ↗

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.Semantic proximity Read ↗

The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.